Medical Device & Implant Manufacturing Process Systems

Usually not. Most device manufacturing runs on USP Purified Water or on deionized water specified by resistivity, because the cleaning validation has to demonstrate removal of manufacturing residues rather than control of a parenteral endotoxin limit. WFI becomes relevant for implants with bloodstream contact or for combination products carrying a drug. Specifying a hot WFI loop by default adds substantial capital and operating cost that a device line often cannot justify.

ASTM F86 is the practice written specifically for metallic surgical implants, covering surface preparation and marking of the implant itself. ASTM A967 is the general specification for chemical passivation of stainless steel parts and equipment, normally paired with ASTM A380 for cleaning and descaling. They are not interchangeable. On an implant line you frequently need both: F86 governs the product, A967 and A380 govern the process equipment that touches it.

ISO 8 is common for general assembly and packaging, and ISO 7 for higher-risk assembly or sterile-barrier operations. The class is driven by the product’s bioburden strategy and by whether terminal sterilization follows, not by a fixed rule. A terminally sterilized device can often be assembled in a less stringent environment than one relying on aseptic presentation, which is where a lot of unnecessary cost gets designed in.

The Quality System Regulation is built around design controls and process validation rather than batch records. For process equipment that means installation and operational qualification tied to a validated manufacturing process, with the equipment evidence feeding the device master record. In practice the deliverables look similar to pharmaceutical IQ/OQ/PQ, but the justification is written against process capability and design inputs rather than against a batch genealogy.

Yes. We are a nationwide contractor and Warsaw is one of the densest concentrations of implant manufacturing anywhere, holding roughly a third of world orthopedic production and about 60 percent of replacement hip and knee manufacturing. The recurring scopes there are implant passivation to ASTM F86, ultrasonic and parts-cleaning lines, DI rinse water and the sanitary distribution feeding them.

Yes, and they are treated as two separate documented activities. Implants follow ASTM F86 for surface preparation, while the tanks, piping and fixtures that contact them are cleaned per ASTM A380 and passivated per ASTM A967. We record procedure, chemistry, contact time, temperature, rinse quality and the final verification for each, because an auditor will ask which standard applied to which surface.

ISO 13485 makes you responsible for controlling suppliers whose work affects product quality, so your contractor has to produce evidence you can put in front of a notified body. That means traceable materials, qualified welders, weld and borescope records, passivation documentation and clean handover packages. We build the documentation as a deliverable rather than assembling it retrospectively, because retrospective packages are where supplier audits find gaps.

Device cleaning validation usually targets manufacturing residues such as cutting fluids, machining debris, polishing compounds and handling contamination, rather than active pharmaceutical ingredient carryover. That changes the analytical methods and the acceptance criteria, and it changes the rinse-water grade you can justify. It also makes the design of the ultrasonic and rinse sequence part of the validation argument rather than a purely mechanical choice.

Yes, including the water, drainage, ventilation and controls around them. The part most often underestimated is the rinse side: final rinse water quality, how it is delivered, how it drains and how it is sampled will determine whether the cleaning validation passes. We specify the rinse loop as part of the line rather than treating it as a utility connection made later by someone else.

Yes, and those projects need the stricter of the two regimes applied deliberately rather than by accident. A combination product can pull 21 CFR 211 requirements, WFI-grade water and Annex 1 thinking onto what otherwise looks like a device line. The engineering decision worth making early is which parts of the facility genuinely need the drug-side standard, so the whole plant is not built to it.

For a typical ISO 7 or ISO 8 suite, testing itself is usually a matter of days, but the sequencing matters more than the duration. Recertification to ISO 14644-2 needs the room in a defined state, so the real planning question is how much production time is lost and whether testing can run across a shutdown. We schedule recertification against your production calendar rather than ours wherever the timing allows.

They matter wherever the room runs continuously, and they matter a great deal in the coastal clusters. California industrial electricity averaged 21.53 cents per kilowatt-hour in 2024 and Massachusetts 18.19, against a national average of 8.13 (EIA). Over ten years the air-change strategy on an ISO 7 room in those states can cost more than the room did to build, which makes recovery testing and recirculation design worth real engineering attention.

Interfaces. The cleanroom contractor assumes the water vendor owns the final rinse specification, the water vendor assumes the cleaning-line supplier does, and the passivation record for the process equipment never gets written because nobody scoped it. None of these are hard engineering problems; they are ownership problems, which is the argument for holding the scopes under a single contract.

Use the form on this page or call 201-450-8280. Useful things to have ready are the device and whether it is terminally sterilized, the cleanroom class you believe you need, the rinse-water grade your cleaning validation assumes, and whether any implant passivation is in scope. If you have a user requirement specification or design inputs, send them; if not, we can help define scope before pricing.

It is the Quality System Regulation for devices, organised around design controls, production and process controls, and corrective and preventive action rather than batch-based drug manufacturing. Design history and device master records replace batch records, which changes what a contractor's documentation has to feed into.

It puts requirements on supplier control, so the manufacturer has to qualify and monitor the contractor, and the contractor's records have to be acceptable as supplier evidence. In practice that means traceable materials, documented procedures and change notification rather than a separate certification for every trade.

It covers surface preparation and marking of metallic surgical implants, including passivation practice for implant materials. It applies to the device itself rather than to the process equipment around it, which is generally treated under ASTM A967 and ASTM A380.

Titanium forms a stable oxide naturally, so it is not passivated in the sense stainless is. What it needs is removal of embedded iron and processing contamination, which ASTM F86 addresses through its cleaning and surface preparation practices. Treating titanium with a stainless passivation recipe is not the same operation.

Its surface chemistry and the nickel content near the surface are central to its biocompatibility, so surface treatment affects device performance rather than only corrosion resistance. Processing is specified tightly and verified analytically, not judged by appearance.

Purified water is common for final rinse of implants and components, with the specification set by the cleaning validation and the residue limits it has to demonstrate. Water for Injection is generally not required unless the device is a combination product with a parenteral drug component.

Through filtered purified water in the final rinse, controlled drying, packaging in a classified environment, and handling procedures that avoid reintroducing particulate. Particulate limits frequently drive the cleanroom classification more than microbial concerns do.

Ethylene oxide requires aeration space and emissions control, radiation is usually contracted out and needs only logistics, and steam requires a sterilisation suite with clean steam. The choice changes the building substantially.

Spent aqueous cleaning solution containing machining fluids, metal fines and detergents, which usually needs treatment before discharge. It is the utility most often overlooked when a cleaning line is purchased as a standalone machine.

Yes, and the facility has to satisfy both frameworks at the points where each applies. That usually means device quality system controls on the device portion and drug cGMP on the drug portion, with the interface defined explicitly rather than left to interpretation.

Packaging and sealing of the sterile barrier system is generally performed in a controlled environment, with the classification set by the risk assessment for the device and the sterilisation method. It is often the tightest classification on the site.